Immunosuppressive and Anti-Inflammatory Properties of Engineered Nanomaterials

Ilinskaya, Anna; Dobrovolskaia, Marina A.

doi:10.1142/9789813140479_0007

Cited by 13 publications

(20 citation statements)

References 88 publications

(127 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is currently one of the most common limiting factors of increasing the doses of cytotoxic cancer medicinal products. 77 Immunosuppressive effects of NMs are not well studied, perhaps due to the fact that immunosuppression is not an acute toxic …”

Section: Immunosuppressionmentioning

confidence: 99%

“…76 In addition, for NMs quite frequently hypersensitivity and immunosuppressive and anti-inflammatory effects are reported and less often autoimmunity. 77 Recently, the induction of protein citrullination by NMs was reported, which may potentially lead to triggering of autoimmune diseases. 78,79 Autophagy is an evolutionarily conserved intracellular process 79 that has a leading role in inflammatory and The immune system and NMPs as a special group of NMs…”

mentioning

confidence: 99%

“…77 This may be useful, eg, as macrophages may be more abundantly present in diseased sites, such as tumors. 36 In addition, NMPs may be able to modulate the immune system in an advantageous way.…”

mentioning

confidence: 99%

See 2 more Smart Citations

A comparison of immunotoxic effects of nanomedicinal products with regulatory immunotoxicity testing requirements

Giannakou¹,

Park²,

Jong³

et al. 2016

IJN

View full text Add to dashboard Cite

Nanomaterials (NMs) are attractive for biomedical and pharmaceutical applications because of their unique physicochemical and biological properties. A major application area of NMs is drug delivery. Many nanomedicinal products (NMPs) currently on the market or in clinical trials are most often based on liposomal products or polymer conjugates. NMPs can be designed to target specific tissues, eg, tumors. In virtually all cases, NMPs will eventually reach the immune system. It has been shown that most NMs end up in organs of the mononuclear phagocytic system, notably liver and spleen. Adverse immune effects, including allergy, hypersensitivity, and immunosuppression, have been reported after NMP administration. Interactions of NMPs with the immune system may therefore constitute important side effects. Currently, no regulatory documents are specifically dedicated to evaluate the immunotoxicity of NMs or NMPs. Their immunotoxicity assessment is performed based on existing guidelines for conventional substances or medicinal products. Due to the unique properties of NMPs when compared with conventional medicinal products, it is uncertain whether the currently prescribed set of tests provides sufficient information for an adequate evaluation of potential immunotoxicity of NMPs. The aim of this study was therefore, to compare the current regulatory immunotoxicity testing requirements with the accumulating knowledge on immunotoxic effects of NMPs in order to identify potential gaps in the safety assessment. This comparison showed that immunotoxic effects, such as complement activation-related pseudoallergy, myelosuppression, inflammasome activation, and hypersensitivity, are not readily detected by using current testing guidelines. Immunotoxicity of NMPs would be more accurately evaluated by an expanded testing strategy that is equipped to stratify applicable testing for the various types of NMPs.

show abstract

Section: Immunosuppressionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

A comparison of immunotoxic effects of nanomedicinal products with regulatory immunotoxicity testing requirements

Giannakou¹,

Park²,

Jong³

et al. 2016

IJN

View full text Add to dashboard Cite

show abstract

“…To achieve these goals, many chemical and biomedical researchers have engineered nanoparticles to carry and locally deliver immunosuppressive agents. [4][5][6][7][8][9][10] This can be considered ''indirect immunosuppression,'' where the nanoparticle solely serves as the delivery vehicle. 7 As an alternative, a small but prevailing body of literature is reassessing direct immunosuppression by nanoparticles to be exploited as a compliment for drug therapies or organ/tissue transplantation that otherwise would be rendered ineffective or rejected by the native immune response.…”

Section: Introductionmentioning

confidence: 99%

“…[4][5][6][7][8][9][10] This can be considered ''indirect immunosuppression,'' where the nanoparticle solely serves as the delivery vehicle. 7 As an alternative, a small but prevailing body of literature is reassessing direct immunosuppression by nanoparticles to be exploited as a compliment for drug therapies or organ/tissue transplantation that otherwise would be rendered ineffective or rejected by the native immune response. [11][12][13][14][15] Reports in the fields of nanotoxicology and nanomedicine are exploring the fundamental mechanisms for both intended and unintended immunosuppression by nanomaterials.…”

Section: Introductionmentioning

confidence: 99%

Nanoparticles and direct immunosuppression

Ngobili

Daniele

2016

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

Targeting the immune system with nanomaterials is an intensely active area of research. Specifically, the capability to induce immunosuppression is a promising complement for drug delivery and regenerative medicine therapies. Many novel strategies for immunosuppression rely on nanoparticles as delivery vehicles for small-molecule immunosuppressive compounds. As a consequence, efforts in understanding the mechanisms in which nanoparticles directly interact with the immune system have been overshadowed. The immunological activity of nanoparticles is dependent on the physiochemical properties of the nanoparticles and its subsequent cellular internalization. As the underlying factors for these reactions are elucidated, more nanoparticles may be engineered and evaluated for inducing immunosuppression and complementing immunosuppressive drugs. This review will briefly summarize the state-of-the-art and developments in understanding how nanoparticles induce immunosuppressive responses, compare the inherent properties of nanomaterials which induce these immunological reactions, and comment on the potential for using nanomaterials to modulate and control the immune system.

show abstract

Gold nanoparticle and polyethylene glycol in neural regeneration in the treatment of neurodegenerative diseases

Aghaie

Jazayeri

Manian

et al. 2018

J of Cellular Biochemistry

View full text Add to dashboard Cite

Gold nanoparticles (GNs) have unique characteristics, for example, stability, biocompatibility, small dimensions, and low toxicity. Several clinical applications have been suggested for GNs, such as diagnosis, imaging, and drug delivery. GNs absorb infrared light, indicating their potential value for imaging. There is growing evidence showing the therapeutic application of GN for drug delivery because of their interaction with the blood-brain barrier and DNA, the latter being associated with their genotoxic effects. GN can also be stimulated to produce high local temperatures, indicating their potential value in photodynamic therapy in the treatment of tumors. The aim of the current review is to summarize the potential applications of GNs in the biomedical field, specifically in neurodegenerative diseases. K E Y W O R D S electrical conductivity properties, gold nanoparticle, membrane sealant, neuroregeneration, polyethylene glycol (PEG)

show abstract

Immunosuppressive and Anti-Inflammatory Properties of Engineered Nanomaterials

Cited by 13 publications

References 88 publications

A comparison of immunotoxic effects of nanomedicinal products with regulatory immunotoxicity testing requirements

A comparison of immunotoxic effects of nanomedicinal products with regulatory immunotoxicity testing requirements

Nanoparticles and direct immunosuppression

Gold nanoparticle and polyethylene glycol in neural regeneration in the treatment of neurodegenerative diseases

Contact Info

Product

Resources

About